Ubrogepant Combined With OnabotulinumtoxinA Effective for Breakthrough Migraine
Presenting at AHS 2022, researchers evaluated the real-world effectiveness of ubrogepant in combination with onabotulinumtoxinA to treat breakthrough migraine.
Presenting at AHS 2022, researchers evaluated the real-world effectiveness of ubrogepant in combination with onabotulinumtoxinA to treat breakthrough migraine.
Researchers sought to assess the epidemiology of comorbid sleep disorders in patients with migraine.
Researchers assessed patients who developed a new-onset neuromuscular disorder the first 6 weeks after receiving either the first or second dose of the COVID-19 vaccine.
Advanced glycation end products (AGE) are a factor in diabetic end-organ damage and several diabetic complications. Investigators studied whether measuring AGE with skin autofluorescence (SAF) could predict diabetic complications.
Decreased ovarian reserve and the number and quality of oocytes often occurs as the ovaries age and can cause fertility disorders and miscarriages. Researchers examined the relationship between thyroid-stimulating hormone levels and ovarian function.